TNFSF13 Protein (T7 tag)
TNFSF13
Origine: Humain
Hôte: Escherichia coli (E. coli)
Recombinant
SDS
N° du produit ABIN7509516
-
-
Antigène
Voir toutes TNFSF13 Protéines
-
TNFSF13
(Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))
-
Type de proteíne
-
Recombinant
-
Origine
-
Humain
-
Source
-
Escherichia coli (E. coli)
-
Purification/Conjugué
-
Cette TNFSF13 protéine est marqué à la T7 tag.
-
Application
-
SDS-PAGE (SDS)
-
Fonction
-
TNFSF13 (Human) Recombinant Protein
-
Séquence
-
MASMTGGQQM GRGSHMAVLT QKQKKQHSVL HLVPINATSK DDSDVTEVMW QPALRRGRGL QAQGYGVRIQ DAGVYLLYSQ VLFQDVTFTM GQVVSREGQG RQETLFRCIR SMPSHPDRAY NSCYSAGVFH LHQGDILSVI IPRARAKLNL SPHGTFLGL.
-
Attributs du produit
-
Human TNFSF13 (O75888, 105 a.a. - 247 a.a.) partial-length recombinant protein with T7-tag at N-terminal expressed in Escherichia coli
-
Purification
-
Escherichia coli expression system
-
Top Product
-
Discover our top product TNFSF13 Protéine
-
-
-
Indications d'application
-
Optimal working dilution should be determined by the investigator.
-
Restrictions
-
For Research Use only
-
-
Format
-
Liquid
-
Buffer
-
20 mM Tris-HCl buffer ( pH 8.0), 0.4M UREA and 10 % glycerol.
-
Stock
-
-20 °C
-
-
Antigène
-
TNFSF13
(Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))
-
Autre désignation
-
TNFSF13 (TNFSF13 Produits)
-
Synonymes
-
APRIL Protein, CD256 Protein, TALL-2 Protein, TALL2 Protein, TRDL-1 Protein, ZTNF2 Protein, 2310026N09Rik Protein, April Protein, Tall2 Protein, Trdl1 Protein, SLAN Protein, ANP32B Protein, april Protein, tnf13 Protein, TNLG7B Protein, TNF superfamily member 13 Protein, tumor necrosis factor (ligand) superfamily, member 13 Protein, acidic leucine-rich nuclear phosphoprotein 32 family member B Protein, TNFSF13 Protein, Tnfsf13 Protein, LOC494442 Protein, tnfsf13 Protein
-
Sujet
-
Tumor necrosis factor (ligand) superfamily, member 13
-
ID gène
-
8741
-
Pathways
-
Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response
-